<DOC>
	<DOCNO>NCT02890173</DOCNO>
	<brief_summary>To evaluate antihypertensive effect safety CS-3150 compare Eplerenone patient essential hypertension .</brief_summary>
	<brief_title>Study CS-3150 Patients With Essential Hypertension</brief_title>
	<detailed_description>Primary objective evaluate antihypertensive effect safety CS-3150 2.5 mg compare Eplerenone patient essential hypertension . Secondary objective evaluate antihypertensive effect safety CS-3150 5.0 mg compare 2.5 mg .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Male female subject age 20 year old informed consent Subjects essential hypertension satisfy follow blood pressure criterion ; Sitting SBP : ≥ 140 mmHg &lt; 180 mmHg Sitting DBP : ≥ 90 mmHg &lt; 110 mmHg Mean 24 hr BP : SBP ≥ 130 DBP ≥ 80 mmHg Secondary hypertension malignant hypertension Diabetic nephropathy diabetes mellitus albuminuria Serum potassium level &lt; 3.5 ≥ 5.1 mEq/L Reversed daynight life cycle include overnight worker eGFR &lt; 60 mL/min/1.73 m^2</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Essential hypertension</keyword>
	<keyword>Mineralocorticoid receptor antagonist</keyword>
	<keyword>Esaxerenone</keyword>
	<keyword>Ambulatory blood pressure monitoring</keyword>
</DOC>